The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial
Abstract
Background Recent reports describe discontinuation-emergent adverse events upon cessation of selective serotonin reuptake inhibitors including dizziness, insomnia, nervousness, nausea, and agitation. We hypothesized that interruption of fluoxetine treatment would be associated with fewer discontinuation-emergent adverse events than interruption of sertraline or paroxetine treatment, based on fluoxetine's longer half-life. Methods In this 4-week study, 242 patients with remitted depression receiving maintenance therapy with open-label fluoxetine, sertraline, or paroxetine for 4-24 months had their maintenance therapy interrupted with double-blind placebo substitution for 5-8 days. The Symptom Questionnaire (SQ), the Discontinuation-Emergent Signs and Symptoms checklist, the 28-item Hamilton Depression Rating Scale, and the Montgomery-Asberg Depression Rating Scale were used to assess somatic distress and stability of antidepressant response. Results Two hundred twenty patients (91%) completed the study. Following interruption of therapy, fluoxetine-treated patients experienced fewer discontinuation-emergent events than either sertraline-treated or paroxetine-treated patients (p Conclusions Abrupt interruption of antidepressant therapy for 5-8 days was associated with the emergence of new somatic and psychological symptoms in patients treated with paroxetine and to a lesser degree sertraline, with few symptoms seen with fluoxetine.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Initially developed for drug trials [309], the DESS is a structured 43-item self-report that utilizes the following scale: 1=new symptom, 2=old symptom but worse, 3=old symptom but improved, 4=old symptom but unchanged, 5=symptom not present.”
In the citing paper
“they are usually reversible and last from a few hours to 6 weeks [5, 16, 97].”
From Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications (2020) · cites this paper as [97]
In the citing paper
“Their frequency and duration depend on the drug discontinued [5, 16, 97].”
From Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications (2020) · cites this paper as [97]
In the citing paper
“and subsequent studies reported that new withdrawal symptoms may occur [97].”
From Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications (2020) · cites this paper as [97]
In the citing paper
“Peaks of onset occur 36 h to 10 days after dose decrease or discontinuation,”
From Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications (2020) · cites this paper as [97]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
Orme, J. G., Reis, J., & Herz, E. J. (1986) · Journal of Clinical Psychology · doi:10.1002/1097-4679(198601)42:1<28::aid-jclp2270420104>3.0.co;2-t · Cited by 777
(1987) · PubMed · Cited by 439
Clinical Pharmacokinetics of Selective Serotonin Reuptake Inhibitors
van Harten, J. (1993) · Clinical Pharmacokinetics · doi:10.2165/00003088-199324030-00003 · Cited by 311
Serotonin Reuptake Inhibitor Withdrawal
Coupland, N. J., Bell, C. J., & Potokar, J. P. (1996) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199610000-00003 · Cited by 303
Paroxetine in the Treatment of Panic Disorder a Randomised, Double-Blind, Placebo-Controlled Study
Oehrberg, S., Christiansen, P. E., Behnke, K., Borup, A. L., Severin, B., Soegaard, J., Calberg, H., Judge, R., Ohrstrom, J. K., & Manniche, P. M. (1995) · British Journal of Psychiatry · doi:10.1192/bjp.167.3.374 · Cited by 261
Selective serotonin reuptake inhibitors: meta-analysis of discontinuation rates
Montgomery, S. A., Henry, J., McDonald, G., Dinan, T., Lader, M., Hindmarch, I., Clare, A., & Nutt, D. (1994) · International Clinical Psychopharmacology · doi:10.1097/00004850-199400910-00008 · Cited by 254
Medication noncompliance in schizophrenia: codification and update.
Young, J. L., Zonana, H. V., & Shepler, L. (1986) · PubMed · Cited by 198
PRICE, J. S., WALLER, P. C., WOOD, S. M., & MACKAY, A. V. P. (1996) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1996.00498.x · Cited by 171
Research works printed but not linked: 3
- Bhaumik, 1996, Treatment outcomes including withdrawal phenomena with fluoxetine and paroxetine in patients with learning disabilities suffering from affective disorders [letter], Hum Psychopharmacol, 11, 337
- Olivier-Martin, 1986, Facteurs psychologiques, observance et resistance aux traitements antidepresseurs (Psychological factors, compliance and resistance to antidepressant treatment) (abstract in English), Encephale, 12, 197
- Young, 1986, Medication noncompliance in schizophrenia, Bull Am Acad Psychiatry Law, 14, 105
Cited by
A systematic review of the associations between dose regimens and medication compliance
Claxton, A. J., Cramer, J., & Pierce, C. (2001) · Clinical Therapeutics · doi:10.1016/s0149-2918(01)80109-0 · Cited by 2,388
Ruhé, H. G., Mason, N. S., & Schene, A. H. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4001949 · Cited by 861
Mayo-Wilson, E., Dias, S., Mavranezouli, I., Kew, K., Clark, D. M., Ades, A. E., & Pilling, S. (2014) · The Lancet Psychiatry · doi:10.1016/s2215-0366(14)70329-3 · Cited by 680
Hirschfeld, R. M. A. (2001) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.v03n0609 · Cited by 661
Bauer, M., Pfennig, A., Severus, E., Whybrow, P. C., Angst, J., Möller, H.-J., & Šon behalf of the Task Force on Unipolar Depressive Disorders (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2013.804195 · Cited by 632
Metadata
- Authors
- Rosenbaum, J. F., Fava, M., Hoog, S. L., Ascroft, R. C., & Krebs, W. B.
- Affiliations
- Massachusetts General Hospital (US)
- Eli Lilly (United States) (US)
- Corresponding author
- Rosenbaum, Jerrold F
- Venue
- Biological Psychiatry
- Publisher
- Elsevier BV
- Published
- 1998-07
- Volume
- 44
- Issue
- 2
- Pages
- 77-87
- ISSN
- 0006-3223 (ISSN-L)
- OpenAlex
- W2022191212
- Semantic Scholar
- c44b2af13ae924269fe757b29bd1bba36e0612f4
- Cited by
- 574
- References
- 40
- Citations by year
- 2026: 27 · 2025: 25 · 2024: 25 · 2023: 22 · 2022: 19 · 2021: 22 · 2020: 22 · 2019: 26 · 2018: 13 · 2017: 12 · 2016: 14 · 2015: 19 · 2014: 11 · 2013: 16 · 2012: 16
- FWCI
- 16.36
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- Biological Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Keywords
- selective serotonin reuptake inhibitors, antidepressant discontinuation syndrome, fluoxetine, sertraline, paroxetine, remitted depression, drug discontinuation, elimination half-life
- MeSH terms
- Adult, Depressive Disorder, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Fluoxetine, Half-Life, Health Status, Humans, Male, Middle Aged, Placebos, Prospective Studies, Psychiatric Status Rating Scales, Surveys and Questionnaires, Serotonin, Substance Withdrawal Syndrome, 1-Naphthylamine, Selective Serotonin Reuptake Inhibitors, Paroxetine, Sertraline
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. https://app.cochat.ai/papers/10.1016/s0006-3223(98)00126-7
- The paper
- Rosenbaum, J. F., Fava, M., Hoog, S. L., Ascroft, R. C., & Krebs, W. B. (1998). Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biological Psychiatry. https://doi.org/10.1016/s0006-3223(98)00126-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.